Metabolon's Untargeted Metabolomics Services Used for Landmark Study Linking a Western Dietary Pattern During Pregnancy to Neurodevelopment Disorders
Metabolomic profiling uncovered how maternal diet and metabolism may contribute to the risk of ADHD and autism in children
MORRISVILLE, N.C., May 28, 2025 /CNW/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced that Metabolon's untargeted metabolomics services were used in a landmark study led by principal investigators Rassmussen, Stokholm, Lasky-Su, and Kelly. The study, published in Nature Metabolism, revealed that blood metabolomic profiling was instrumental in uncovering biological mechanisms linking maternal diet and metabolism to neurodevelopmental disorders and in validating these associations through a consistent metabolic signature observed across multiple independent cohorts.
Globally, attention-deficit/hyperactivity disorder (ADHD) affects approximately 5–7% of children and adolescents and 2–5% of adults, with variations in prevalence influenced by regional differences in diagnostic practices. Autism spectrum disorder (ASD) has an estimated global prevalence of about 1–2% (around 1 in 100 children), although some recent studies suggest rates up to 2.3%. Boys are diagnosed with autism roughly four times more frequently than girls.
Horner et al. conducted a large-scale analysis involving over 60,000 mother-child pairs, with untargeted blood metabolomic profiling performed on a subset of approximately 1,500 pairs, featuring longitudinal maternal and child sampling, to identify metabolic dietary signatures associated with neurodevelopmental risk. Metabolon's Global Discovery Panel, an untargeted metabolomics platform, was used to generate high-resolution metabolic profiles from maternal plasma during pregnancy and from children at multiple developmental stages. Subanalyses of the child metabolomic data showed that the most pronounced associations with neurodevelopmental outcomes were linked specifically to maternal diet during pregnancy, highlighting the prenatal period as a particularly sensitive window of exposure.
The study revealed that consuming a Western diet during pregnancy significantly increased the risk of autism and ADHD in infants and children. Dietary survey data from COPSAC2010, a mother-child cohort based in Denmark, initially showed that moderate dietary shifts toward a Western dietary pattern were associated with increased ADHD risk by 66% and autism by 122%. Encouragingly, even modest improvements away from Western eating habits could meaningfully lower these risks, highlighting practical implications for prenatal nutrition. This Western dietary pattern was externally validated in the U.S.-based VDAART cohort using blood metabolomic modeling aligned with independently assessed food frequency questionnaires. Moreover, the association between this dietary pattern and ADHD risk was replicated across three independent mother-child cohorts, strengthening the inference for ADHD. Metabolomic profiling identified 15 circulating metabolites that significantly mediated the relationship between diet and neurodevelopment, offering insights into potential biological mechanisms.
"This study analyzed maternal dietary patterns during pregnancy and evaluated children's mental health at age 10. Using dietary surveys and blood metabolomics, we discovered that a Western dietary pattern in pregnancy was strongly associated with increased risk of ADHD and autism. By comparing metabolomic profiles from mid-pregnancy in the COPSAC cohort with early and late pregnancy samples from the VDAART cohort, we were able to infer that early to mid-pregnancy may represent a particularly sensitive window during which maternal diet can shape child neurodevelopment," said lead author of the study and lead COPSAC researcher Morten Arendt Rassmussen.
Co-author and Principal Investigator of the VDAART cohort Jessica Lasky-Su added, "One of the most compelling aspects of this study is that metabolomic profiling was able to identify consistent dietary signals linked to neurodevelopmental risk across cohorts that differ significantly in socioeconomic status, race, and geographic setting. These insights pave the way for targeted nutritional interventions during pregnancy that could potentially reduce the risk of neurodevelopmental disorders in children across a broad range of populations. The breadth of metabolites captured on the Metabolon platform was instrumental in enabling us to draw these conclusions."
"We're extremely pleased to support the international efforts of the COPSAC and VDAART investigative teams led by Morten Arendt Rassmussen, Jakob Stokholm, Jessica Lasky-Su, and Rachel Kelly," said Greg Michelotti, Director of Population Health at Metabolon. "This study shows the power of metabolomics and specifically Metabolon's industry-leading untargeted metabolomics services to elucidate novel insights for caregivers and parents worldwide seeking the healthiest possible outcomes for children."
Learn more about this groundbreaking scientific research here.
Learn more about Metabolon's untargeted metabolomics services here.
About Metabolon
Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other 'omics' technologies. With more than 20 years, 10,000+ projects, 3,500+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technology, and bioinformatics techniques. Metabolon's Global Discovery Panel is powered by the world's largest proprietary metabolomics reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.
About Metabolomics
Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
19 hours ago
- Cision Canada
World-first clinical trial confirms exercise improves survival for colon cancer Français
A Canadian Cancer Society-funded trial reveals that guided exercise can save and prolong lives by reducing risk of cancer recurrence and second cancers TORONTO, June 1, 2025 /CNW/ - A groundbreaking clinical trial funded by the Canadian Cancer Society (CCS) shows that physical activity can significantly improve outcomes for people with colon cancer. Researchers say the study is the first in the world to use structured exercise to increase cancer survival. The trial results, presented today at the American Society of Clinical Oncology annual conference and published in the New England Journal of Medicine, have the potential to change clinical practice. They show that, when incorporated into cancer care for people with colon cancer, a structured exercise program reduces the risk of cancer recurrence and of new primary cancers developing. "Our findings show that exercise is no longer just a quality-of-life intervention for cancer patients that can be offered when and where possible," says study co-chair Dr Kerry Courneya, a professor of kinesiology at the University of Alberta and Canada Research Chair in Physical Activity and Cancer. "It is a treatment for colon cancer that must be made available to all patients." Colorectal cancer is the second leading cause of cancer death in Canada. Last year, an estimated 25,200 Canadians were diagnosed with colorectal cancer and 9,400 people died from it. To improve outcomes, a team led by Dr Courneya and Dr Chris Booth – study co-chair, medical oncologist at Kingston Health Sciences Centre and professor of oncology at Queen's University – has been working with the Canadian Cancer Trials Group (CCTG) on this first-of-its kind trial. The 17-year international trial involved 889 people, all of whom had been diagnosed with and treated for colon cancer. After having surgery and chemotherapy, participants were given a 3-year structured exercise program or standard health education materials that are currently given to patients. Each participant in the exercise program chose their own forms of moderate-intensity exercise – from walking to pickleball – with the goal of adding 2.5 hours of exercise per week to their regular activity schedule. The outcome: those who received the exercise program had a 28% lower risk of recurrence and new cancers and a 37% lower risk of death. "This is the first clinical trial in the world designed to answer whether exercise can improve cancer survival, and the results are clear," says Dr Booth. "The next step is to put this into practice. That means health systems will need to invest in behaviour support programs as part of standard care." The researchers are currently conducting a comprehensive health economic analysis. According to Dr Booth, they anticipate that the program will be "remarkably cost-effective compared to many new cancer drugs," making it sustainable for health systems. Terri's story Terri Swain-Collins was diagnosed with stage 3 colon cancer in 2021 after a screening test led to further investigation. Following treatment including surgery and chemotherapy, she was invited to join Dr Booth and Dr Courneya's clinical trial. During the trial, she worked closely with a physiotherapist to establish and maintain a fitness routine personalized to her needs. "One of the biggest benefits was having a semi-structured routine that works for my lifestyle with someone to hold me accountable," says Terri. "Simply being told to exercise by a physician wouldn't have been enough to get me to where I am today; having someone walk alongside me, guide me and check in regularly was what truly made it possible." Now, 3 years later, Terri continues to walk 3 times a week, feels fit and remains cancer-free. She says she is grateful for the impact of the program on her health and well-being. "By bridging the gap between bold ideas and routine practice, clinical trials are essential to driving research progress that can benefit patients," says Dr Stuart Edmonds, Executive Vice President, Mission, Research and Advocacy at CCS. "The results of this trial have the potential to save and improve lives for the tens of thousands of people in Canada affected by colorectal cancer each year, and we are proud our donors enabled us to support it." The international study co-chair was Dr Janette Vardy, from The University of Sydney (Australia) with funding from National Health and Medical Research Council. The UK team was led by Dr Victoria Coyle at Queen's University of Belfast, supported by Cancer Research UK. About the Canadian Cancer Society The Canadian Cancer Society works tirelessly to save and improve lives. We raise funds to fuel the brightest minds in cancer research. We provide a compassionate support system for all those affected by cancer, across Canada and for all types of cancer. Together with patients, supporters, donors and volunteers, we work to create a healthier future for everyone. Because to take on cancer, it takes all of us. It takes a society. Help us make a difference. Call 1-888-939-3333 or visit today. About the Canadian Cancer Trials Group The Canadian Cancer Trials Group (CCTG) is a cancer clinical trials research cooperative that runs phase I–III trials to test anti-cancer and supportive therapies at over 85 hospitals and cancer centres across Canada. From their operations centre at Queen's University, CCTG has supported more than 600 trials enrolling 100,000 patients from 40 countries on 6 continents through a global network of 20,000 investigators and clinical trial staff. CCTG is the Canadian Coordinating Clinical Trial Network for the US NCTN and is a national program of the Canadian Cancer Society. CCTG's aim is to improve survival and quality of life for all people with cancer. Learn more at
Cision Canada
21 hours ago
- Cision Canada
/R E P E A T -- MEDIA ADVISORY - Walking in Support of the 322,000+ people in Canada with Crohn's or colitis/ USA
Every 48 minutes – another Canadian is diagnosed with Crohn's or colitis; by 2035, 470,000+ Canadians will be living with IBD TORONTO, May 30, 2025 /CNW/ - WHAT: On Sunday, June 1, 2025, Crohn's and Colitis Canada, along with Canada's Inflammatory Bowel Disease (IBD) community, will participate in Gutsy Walk, a national fundraising event that supports the 322,000+ people living with Crohn's or colitis. Gutsy Walk, Crohn's and Colitis Canada's largest fundraising initiative, raises funds that go directly towards national research, advocacy, and patient programs. WHO: Those living with Crohn's or colitis, community members, friends, family and local representatives. WHEN: Sunday, June 1, 2025. Event start times may vary by location. WHERE: 30+ locations nationwide – from coast to coast. To register a team, donate and view locations, visit: WHY: There is no cure for Crohn's or colitis. Treatment focuses on achieving and maintaining remission, minimizing complications, preventing lasting intestinal damage, and improving quality of life. Crohn's and colitis are lonely diseases, with stigma and isolation added onto physical symptoms. SPOKESPERSON QUOTES: Jayda Sutton of Oakville, ON: Longstanding participant who lives with colitis and is the Ontario Provincial Honourary Chair. "I walk to honour my journey, my son Grayson who passed away at eight months gestation due to complications related to my colitis, my daughter Alyssa, my husband Chris, my parents and everyone who has stood with me. I want to use my story to highlight the quiet victories – getting back up when you feel defeated." Kate Lee, VP, Research & Patient Programs, Crohn's and Colitis Canada:"Gutsy Walk is a celebration of resilience. These are isolating diseases, which makes Gutsy Walk an important moment for those affected to come together and contribute to a better future for themselves." We are on a relentless journey to cure Crohn's and colitis and improve the quality of life of everyone affected by these diseases. Get the latest Gutsy Walk information on Instagram and Facebook - @gutsywalk and @getgutyscanada, as well as For information on Crohn's and Colitis Canada, visit
Cision Canada
a day ago
- Cision Canada
The Princess Margaret Cancer Foundation Raises Over $1.16 Million at Inaugural Cricket to Conquer Cancer - Canada's Largest Street Cricket Fundraiser
Hundreds united to support life-saving cancer research and create a world free from the fear of cancer MISSISSAUGA, ON, May 31, 2025 /CNW/ - More than 400 cricketers gathered at Celebration Square as The Princess Margaret Cancer Foundation (The PMCF), presented by TD, hosted the inaugural Cricket to Conquer Cancer — the largest street cricket fundraiser in Canada. This landmark event signalled a major moment in Canada's evolving sports landscape and serves as a powerful symbol of community, culture, and hope. "This event is about rallying a community, celebrating diversity, and changing the way cancer is understood, prevented, diagnosed and treated," said Dr. Miyo Yamashita, President and CEO, The Princess Margaret Cancer Foundation. "We are grateful to all the participants and supporters who took to the pitch today to raise funds that will improve cancer outcomes and provide brighter tomorrows for patients here in Canada and around the globe." This exciting first-of-its-kind fundraising event united cancer survivors, caregivers, athletes, celebrities and supporters of all backgrounds in one shared mission: to create a world free from the fear of cancer. "I felt powerless when my mom was diagnosed with breast cancer and when my close friend, Kenroy, passed away from this disease," said Carlos Brathwaite, international cricket star. "I'm proud to bring my passion for cricket to Canada to help launch this event and raise funds for cancer research that can help transform cancer care and treatment everywhere– including my home, Barbados." With 2 in 5 Canadians facing a cancer diagnosis in their lifetime, the event was more than just a game—it was a community movement for collective impact. Proceeds will benefit life-saving research at Princess Margaret Cancer Centre, one of the world's leading cancer research and treatment centres. Top fundraising teams had the unique opportunity to draft celebrity players onto their teams through a celebrity draft including notable ambassadors Jully Black, Jamaal Magloire, Dwayne De Rosario and Carlos Brathwaite. These household names joined local teams on the pitch, highlighting the inclusive and celebratory nature of the event. "As a daughter of Jamaican immigrants, cricket was a source of endless joy in my family," said Jully Black, Canadian singer-songwriter and artist. "This cause is deeply personal. Cancer has touched every corner of my life—my father is a proud survivor, sadly my mother and grandmother passed away from the disease, and at 27 years old, I too, faced my own cancer scare. These experiences left a profound impact on me. I jumped at the opportunity to champion a cause that uplifts, educates, and unites communities to bring hope in the face of a cancer diagnosis." Cricket to Conquer Cancer's event included a full day of family-friendly festivities with cricket matches, live musical performances, food trucks, cultural cuisine, and interactive cricket experiences for all ages. While this year's fundraiser has come to a close, The Princess Margaret encourages new and returning participants to register online for next year's Cricket to Conquer Cancer event at ABOUT PRINCESS MARGARET CANCER FOUNDATION The Princess Margaret Cancer Foundation is Canada's largest cancer charity. We're dedicated to raising funds for Princess Margaret Cancer Centre, one of the world's leading cancer research and treatment centres, known for its breakthrough discoveries that transform patient outcomes. Together, our work benefits cancer patients everywhere in our mission to create a world free from the fear of cancer. Through philanthropy, fundraising events, and our world-leading lottery program, we're changing how the world understands, prevents, diagnoses, and treats cancer, benefitting patients at The Princess Margaret, throughout Canada, and around the world.
